BioCentury | Sep 12, 2020
Product Development

Galapagos gains on Phase II win for systemic sclerosis candidate

Galapagos’ investors rewarded a clinical win on Friday for ziritaxestat, which met its primary endpoint in the Phase IIa NOVESA trial in patients with cutaneous systemic sclerosis.  The company gained €7.55 (7%) to €115.50 on Euronext and $11.05...
BioCentury | Aug 19, 2020
Product Development

Filgotinib setback a blow to building franchise around Gilead-Galapagos therapy

After a surprise setback at FDA for filgotinib in rheumatoid arthritis caused Galapagos to lose more than $3 billion in market cap, two investors who spoke with BioCentury questioned whether the JAK inhibitor still had a chance to...
BioCentury | Jul 24, 2020
Finance

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

...this year for its lead program, INZ-701 to treat calcification disorders; it is a recombinant ENPP1...
...included crossover investors (see “Piling In” ). Targets ADORA2A - Adenosine A2A receptor ENPP1 - Ectonucleotide pyrophosphatase/phosphodiesterase 1 Paul...
BioCentury | Jul 3, 2020
Finance

On heels of $100M raise, Annexon joins burgeoning IPO queue

...plans to submit an IND this year for INZ-701, an enzyme replacement therapy to treat ENPP1...
...6 Btk - Bruton’s tyrosine kinase C1q - Complement component 1 q subcomponent ENPP1 - Ectonucleotide pyrophosphatase/phosphodiesterase 1 Sandi...
BioCentury | Feb 5, 2020
Deals

Gilead signals ‘urgency’ for M&A, working ‘night and day’ on coronavirus response

To execute on its plan to launch 10 transformative medicines in 10 years, Gilead will make M&A a priority in bolstering its pipeline, CEO Daniel O’Day said on the company’s earnings call Tuesday. The company...
BioCentury | Jan 25, 2020
Emerging Company Profile

Aluda: targeting the fundamentals

Five years after its launch, Aluda is pulling back the curtain on its pipeline, leading with a first-in-class anti-VIM therapy for fibrotic indications. CEO Ruihuan Chen co-founded Aluda Pharmaceuticals Inc. in 2015 after 13 years...
BioCentury | Jan 24, 2020
Finance

iOnctura taps European syndicate for series A to bring two ‘best-in-class’ programs to the clinic

On the strength of its new €15 million ($16.6 million) series A round, iOnctura believes it can have two best-in-class oncology candidates in the clinic within a year. Created in 2017 by former Merck KGaA...
BioCentury | Jan 16, 2020
Company News

Galapagos to build fibrosis pipeline via extended Fibrocor partnership

In a move that could refill its fibrosis pipeline, Galapagos expanded its year-old collaboration with Fibrocor, adding options to exclusively license four fibrosis programs. Under the original deal, announced December 2018, Toronto-based Fibrocor Therapeutics L.P...
BioCentury | Jan 16, 2020
Finance

Frazier taking new company creation angle with $617M fund

...in cancer immunotherapy. The firm first seeded Mavupharma with $1 million to explore the target, ENPP1...
...Raises $20M” ). By early 2019, Mavupharma had chosen a candidate for clinical studies: oral ENPP1...
...Jamie Brush to partner, and Gordon Empey to partner and general counsel. Targets ENPP1 - Ectonucleotide pyrophosphatase/phosphodiesterase 1...
BioCentury | Jan 10, 2020
Company News

Boehringer continues fibrosis drive via acquisition of Enleofen assets

The acquisition of Enleofen’s preclinical IL-11 inhibition platform is the latest in a string of deals by Boehringer to build out its fibrosis tool kit, giving the German pharma therapies against a new target for...
Items per page:
1 - 10 of 52